Mitochondrial Disorders Treatment Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

 

Mitochondrial Disorders Treatment Market

Mitochondrial disorders are a group of genetic diseases that are caused by mutations in the mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) that affect the functioning of the mitochondria. Mitochondria are organelles found in every cell in the body that are responsible for producing energy in the form of ATP (adenosine triphosphate). When mitochondria do not function properly, they can cause a variety of symptoms such as muscle weakness, neurological problems, developmental delays, and organ failure. There are currently no cures for mitochondrial disorders, but there are treatments available that can help manage symptoms and improve quality of life.

The Mitochondrial Disorders Treatment Market is expected to grow significantly over the next few years, driven by increasing awareness of these disorders, advancements in diagnostic techniques, and the development of novel therapeutics. The market was valued at approximately $497.4 million in 2016 and is projected to reach $773.7 million by 2025, with a compound annual growth rate (CAGR) of 5.1%.

One of the main treatments for mitochondrial disorders is supportive care, which includes measures such as physical therapy, occupational therapy, and nutritional support. These treatments aim to manage symptoms and improve quality of life for patients. In addition to supportive care, there are also several drugs that have been approved by regulatory agencies for the treatment of mitochondrial disorders.

One such drug is EPI-743, which was approved by the US Food and Drug Administration (FDA) in 2019 for the treatment of Leigh syndrome, a severe form of mitochondrial disease that affects the central nervous system. EPI-743 is a synthetic form of a naturally occurring compound called coenzyme Q10 (CoQ10), which plays a key role in the mitochondrial respiratory chain. EPI-743 has been shown to improve the functioning of the respiratory chain and reduce oxidative stress in cells, leading to improvements in neurological symptoms in patients with Leigh syndrome.